FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1461-1463 April 1, 2004 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The realization that human cancers express cancer-associated antigens has stimulated research into the development of immunotherapies to mediate the regression of established tumors. There are three requirements for an effective immunotherapy for cancer (Figure 1). A sufficient number of avid tumor-reactive lymphocytes must be present in the tumor-bearing host, these lymphocytes must be capable of reaching and extravasating at the site of the cancer, and the lymphocytes at the tumor site must have appropriate effector mechanisms to destroy cancer cells.

View larger version (64K): [in this window] [in a new window]   Figure 1. Two Approaches to Immunotherapy. The two main approaches to immunotherapy for cancer are vaccine therapy and cell-transfer therapy. . . . [Full Text of this Article]

 

Source Information

From the National Cancer Institute, Bethesda, Md.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.